Mangoceuticals (NASDAQ: MGRX) announced on July 30, 2026, a definitive merger agreement with Nuclea Energy Inc., a Canadian company developing the Morpheus microreactor. The transaction brings an advanced nuclear reactor directly onto U.S. public markets, with all that entails in terms of capital access and institutional visibility.
Nuclea was founded in August 2023 and is headquartered in Mississauga, Ontario. Its Morpheus reactor is a factory-built modular microreactor, lead-cooled and graphite-moderated, with an electrical output ranging from 3.5 to 50 megawatts. The design relies on passive safety features inherent to the coolant: near-atmospheric operating pressure and natural convection cooling requiring no pumps. The overall architecture is deliberately simple, reducing operational complexity in the field.
Under the terms of the agreement, a newly created subsidiary of Mangoceuticals will merge with Nuclea. Nuclea shareholders will receive exchangeable shares in the subsidiary, convertible on a one-for-one basis into Mangoceuticals common stock with equivalent economic and voting rights, subject to Nasdaq requirements. Upon closing, Nuclea will operate as an indirect subsidiary of Mangoceuticals and will continue advancing its reactor technology through an 18-month development plan aimed at regulatory completion and commercial readiness.
The rationale behind the deal is straightforward. Demand for continuous, carbon-free electricity is rising alongside the expansion of artificial intelligence infrastructure and hyperscale data centers. Microreactors are designed to serve precisely the applications that traditional power grids cannot efficiently reach: defense installations, remote sites, and energy-intensive industrial facilities. Josef Freundorfer, CEO of Nuclea, stated that the public listing will provide the capital needed to bring Morpheus to its first operational delivery.
For Mangoceuticals, this represents a sharp strategic pivot. The company has until now been known for men’s health products and telemedicine services. Entering advanced nuclear energy through this merger fundamentally reshapes the company’s profile. Jacob Cohen, CEO of Mangoceuticals, cited Nuclea’s reactor design, technical team, and commercialization roadmap as the decisive factors in the decision.
The modular microreactor sector is expanding rapidly and the race for capital is already well underway among multiple players. With Morpheus, Nuclea targets a specific segment: mid-range power output, inherent safety, and centralized manufacturing. If the 18-month plan holds, the company could file for regulatory approval with a financial structure already reinforced by its public listing — a path that other advanced reactor developers are attempting to replicate, with results still uncertain. For Nuclea, the differentiating factor may prove to be precisely its decision to access public markets before completing detailed engineering.
